Displaying drugs 276 - 300 of 407 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Elapegademase | 115000.0 C1797H2795N477O544S12 |  | A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. | Adenosine Deaminase Inhibitors |
| Pegunigalsidase alfa | 116000.0 C2060H3130N552O601S27 | | A recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease. | Enzymes |
| Avalglucosidase alfa | 124000.0 C4490H6818N1197O1299S32 | | A lysosomal glycogen-specific enzyme that is used to treat patients one year of age and older with late-onset Pompe disease, or lysosomal acid alpha-glucosidase (GAA) deficiency. | Enzymes |
| Albutrepenonacog alfa | 125000.0 C5077N7846O1588PS67 |  | A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. | Albumins / Amino Acids, Peptides, and Proteins / Biological Factors / Blood Coagulation Factors / Blood Proteins / Drugs that are Mainly Renally Excreted / Enzyme Precursors / Enzymes and Coenzymes / Hemostatics / Protein Precursors / Proteins / Recombinant Proteins |
| Pancrelipase | 131000.0 | | A purified form of porcine pancreatic lipase, amylase, and protease enzymes used to treat malabsorption associated with pancreatic insufficiency resulting from cystic fibrosis and pancreatitis. | Enzyme Preparations |
| Asparaginase Erwinia chrysanthemi | 140000.0 C1546H2510N432O476S9 |  | An asparagine-specific enzyme used as part of a chemotherapeutic regimen to treat patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. | Amidohydrolases / Antineoplastic Agents / Asparagine-specific Enzyme |
| Evolocumab | 141800.0 C6242H9648N1668O1996S56 |  | A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. | Anticholesteremic Agents / Hypolipidemic Agents Indicated for Hyperlipidemia / PCSK9 Inhibitor |
| Human immunoglobulin G | 142682.3 C6332H9826N1692O1980S42 |  | A purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders. | Antibodies / Human Immunoglobulin G / Immunoglobulin G / Immunoglobulins / Immunologic Factors / Immunoproteins / Serum Globulins |
| Raxibacumab | 142844.5367 C6320H9794N1702O1998S42 |  | A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate. | Antibacterial monoclonal antibodies / Specific Immunoglobulins |
| Eptinezumab | 143000.0 | | A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults. | Calcitonin Gene-related Peptide Antagonist |
| Satralizumab | 143000.0 | | A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). | Interleukin Inhibitors |
| Ibritumomab tiuxetan | 143375.5 C6382H9830N1672O1979S54 |  | A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. | Various Therapeutic Radiopharmaceuticals |
| Nivolumab | 143597.3811 C6362H9862N1712O1995S42 |  | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. | Antibodies, Monoclonal / PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Ramucirumab | 143600.0 C6374H9864N1692O1996S46 |  | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. | Angiogenesis Inhibitors / Antibodies, Monoclonal / VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors |
| Basiliximab | 143801.3 C6378H9844N1698O1997S48 |  | A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. | Interleukin Inhibitors |
| Rituximab | 143859.7 C6416H9874N1688O1987S44 |  | A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. | Antibodies, Monoclonal / CD20 (Clusters of Differentiation 20) inhibitors |
| Tositumomab | 143859.7 C6416H9874N1688O1987S44 |  | A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope. | Iodine (131I) Compounds |
| Maftivimab | 143948.11 C6368H9886N1706O2008S46 | | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. | Antiviral Agents |
| Dostarlimab | 144000.0 C6420H9832N1680O2014S44 | | An anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options. | PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Naxitamab | 144000.0 | | A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. | Glycolipid Disialoganglioside-directed Antibody |
| Burosumab | 144100.0 C6388H9904N1700O2006S46 | | A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Blood Proteins / Drugs Affecting Bone Structure and Mineralization / Drugs for Treatment of Bone Diseases / Fibroblast Growth Factor-23 Blocking Antibodies / Globulins / Immunoglobulins / Immunoproteins / Musculo-Skeletal System / Proteins / Serum Globulins |
| Adalimumab | 144190.3 C6428H9912N1694O1987S46 |  | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Infliximab | 144190.3 C6428H9912N1694O1987S46 |  | A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Tildrakizumab | 144400.0 C6426H9918N1698O2000S46 | | An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. | Interleukin Inhibitors |
| Denosumab | 144700.0 C6404H9912N1724O2004S50 |  | A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. | Antibodies, Monoclonal, Humanized / Bone Density Conservation Agents / RANK Ligand Inhibitor |
Displaying drugs 276 - 300 of 407 in total